Develops treatment software for brachytherapy. Commercializes devices used in brachytherapy. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 7% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 5.4× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 13% of them.
No analyst target is on record for this company.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Growth: Sales growth trails the sector average.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
Sales run at $523K a year. A small number, but proof the product has real buyers.
A loss of $5.1M against $523K in annual sales.
The stock sits at $0.30. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 2.8 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, ITOC sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: ITOC is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown, the price history.